WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 8, 954-967. Research Article ISSN 2277–7105

POST-COVID-19 AND ITS IMPACT ON THE CARDIOVASCULAR SYSTEM: EMERGING RISKS AND LONG-TERM CONSEQUENCES

[1]*Dr. Urvashi Marotrao Belkhude and [2]Dr. Nitin Vishvanath Aalapure

[1]Assistant Professor, Anatomy Department, Bhausaheb Mulak Ayurved College & R H, Butibori.

[2]Assistant Professor, Surgery Department, Shree Saptashrungi Ayurved Mahavidyalaya & Hospital, Nashik.

Article Received on
25 February 2025,

Revised on 18 March 2025,
Accepted on 07 April 2025

DOI: 10.20959/wjpr20258-36267

***Corresponding Author**
Dr. Urvashi Marotrao Belkhude
Assistant Professor,
Anatomy Department,
Bhausaheb Mulak Ayurved College & R H, Butibori.

ABSTRACT

COVID-19 has significantly impacted the cardiovascular system, leading to complications such as myocarditis, pericarditis, arrhythmias, heart failure, and thromboembolic events. The virus induces endothelial dysfunction, hypercoagulability, and direct myocardial injury, increasing long-term cardiovascular risks. Persistent inflammation and autonomic dysregulation further exacerbate these complications. Beyond the heart, COVID-19 causes fibrotic changes, microvascular damage, and immune dysregulation in multiple organs, contributing to post-COVID syndrome. The rise in cardiovascular diseases post-pandemic necessitates long-term monitoring and targeted management strategies. Management includes anticoagulants, beta-blockers, ACE inhibitors, and anti-inflammatory agents, along with lifestyle modifications such as exercise, diet, and stress management. Regular cardiac assessments through ECG, echocardiography, and MRI are crucial for early detection. Further research is essential to understand the long-term impact of COVID-19 on cardiovascular health. Public health strategies should focus on vaccination, early detection, and rehabilitation to reduce morbidity and mortality.

KEYWORDS: COVID-19, cardiovascular complications, myocarditis, post-COVID syndrome, endothelial dysfunction.

INTRODUCTION

COVID-19, caused by the SARS-CoV-2 virus, emerged as a global pandemic in 2019, significantly impacting public health, economies, and healthcare systems. The virus primarily affects the respiratory system but has also shown profound effects on multiple organ systems, particularly the cardiovascular system. As the pandemic progressed, researchers observed an increase in cardiac complications, including myocarditis, arrhythmias, and thromboembolic events.

Vaccination campaigns were initiated worldwide to control the spread of COVID-19. While vaccines have been effective in reducing severe infections and mortality, some concerns regarding post-vaccination cardiac effects, such as myocarditis in young individuals, have been raised. However, the benefits of vaccination in preventing severe disease far outweigh the risks. Despite vaccination efforts, post-COVID-19 complications, often referred to as "long COVID," have led to a surge in cardiovascular issues, necessitating further investigation.

NEED FOR STUDY

With the increasing prevalence of cardiac complications post-COVID-19, it is essential to study the underlying mechanisms, long-term consequences, and effective management strategies. This study aims to highlight the cardiovascular implications of COVID-19, including disease pathology, anatomical changes, and rising trends in cardiac disorders.

MATERIALS AND METHODS

A review of existing literature, clinical studies, and case reports related to post-COVID-19 cardiovascular effects was conducted. Data from peer-reviewed journals, hospital records, and global health organizations were analyzed to understand the correlation between COVID-19 and cardiovascular diseases.

What is COVID-19?

COVID-19 is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It was first identified in Wuhan, China, in late 2019 and quickly spread worldwide, leading to a global pandemic. SARS-CoV-2 primarily affects the respiratory system, but its impact extends to multiple organ systems, including the cardiovascular, neurological, and renal systems.

MODE OF TRANSMISSION

COVID-19 spreads primarily through:

1. **Respiratory Droplets:** When an infected person coughs, sneezes, or talks, virus-loaded droplets can be inhaled by others.
2. **Direct Contact:** Touching contaminated surfaces and then touching the face, nose, or mouth can lead to infection.
3. **Aerosolized Particles:** In enclosed spaces, tiny viral particles can remain suspended in the air and increase transmission risk.

Symptoms of COVID-19

COVID-19 presents with a wide spectrum of symptoms, ranging from mild to severe. Common symptoms include:

- Fever
- Cough
- Shortness of breath
- Fatigue
- Sore throat
- Loss of taste and smell
- Muscle aches
- Gastrointestinal symptoms (diarrhea, nausea)

In severe cases, COVID-19 can lead to **acute respiratory distress syndrome (ARDS)**, multi-organ failure, and death, particularly in individuals with underlying health conditions such as diabetes, hypertension, and cardiovascular disease.

Management of COVID-19

The management of COVID-19 involves **supportive care, antiviral therapy, immune-modulating treatments, and vaccination.**

1. **Supportive Care:** Mild cases require rest, hydration, and symptomatic treatment (e.g., paracetamol), while severe cases may need hospitalization, oxygen therapy, and intensive care.
2. **Antiviral Therapy: Remdesivir** shortens hospital stays, while **Paxlovid and Molnupiravir** prevent disease progression in high-risk patients.
3. **Corticosteroids: Dexamethasone and Methylprednisolone** reduce inflammation in severe cases requiring oxygen support.

4. **Respiratory Support:** Includes **oxygen therapy, non-invasive ventilation (CPAP/BiPAP), mechanical ventilation,** and **ECMO** for critical cases.
5. **Anticoagulation: Heparin and Enoxaparin** prevent blood clots, reducing the risk of **DVT and pulmonary embolism.**
6. **Immunomodulators: Tocilizumab (IL-6 inhibitor)** and **Baricitinib (JAK inhibitor)** help control severe inflammation.
7. **Vaccination:** mRNA (Pfizer, Moderna) and vector-based (AstraZeneca, J&J) vaccines significantly reduce severe disease, hospitalization, and mortality.

PATHOLOGICAL IMPACT ON THE CARDIAC SYSTEM

Although COVID-19 primarily affects the lungs, the virus has significant effects on the cardiovascular system. The mechanisms by which SARS-CoV-2 impacts the heart include **direct viral invasion, immune system overactivation, and vascular inflammation**.

1. Endothelial Dysfunction

- The endothelium (inner lining of blood vessels) is a key target of SARS-CoV-2.
- The virus binds to **angiotensin-converting enzyme 2 (ACE2) receptors**, which are highly expressed in endothelial cells, leading to **vascular inflammation, increased clot formation, and microvascular dysfunction**.
- This can result in **hypertension, thrombosis, and organ damage**.

2. Hypercoagulability (Increased Blood Clot Formation)

- COVID-19 causes an **abnormal clotting tendency**, leading to:
  - **Deep Vein Thrombosis (DVT):** Blood clots in deep veins, often in the legs.
  - **Pulmonary Embolism (PE):** Blood clot that travels to the lungs, potentially fatal.
  - **Stroke:** Due to clot formation in brain arteries.
- This hypercoagulability is linked to **increased D-dimer levels**, a biomarker for clot formation.

3. Myocardial Injury

- SARS-CoV-2 can directly infect **cardiac myocytes**, leading to myocarditis (inflammation of the heart muscle).
- The **immune response and cytokine storm** contribute to cardiac cell damage.
- Increased stress on the heart can result in **acute coronary syndromes and heart failure**.

4. Arrhythmias (Irregular Heartbeats)

- COVID-19 affects the electrical conduction of the heart, leading to:
  - **Atrial fibrillation (AFib):** An irregular, often rapid heartbeat.
  - **Ventricular tachycardia (VT):** A life-threatening fast heart rhythm.
  - **Bradycardia:** Abnormally slow heart rate.
- Electrolyte imbalances, inflammation, and hypoxia contribute to arrhythmias.

ANATOMICAL CHANGES IN THE BODY AFTER COVID-19

COVID-19 affects multiple organ systems beyond the respiratory tract, leading to significant **anatomical and physiological changes** in the body. The virus not only causes acute damage but also leaves long-term sequelae, commonly referred to as **"long COVID"** or **"post-acute sequelae of SARS-CoV-2 infection (PASC)."** Below are the key anatomical changes observed in various organ systems after COVID-19.

1. Cardiovascular System

The heart and blood vessels are major targets of COVID-19 due to the presence of **angiotensin-converting enzyme 2 (ACE2) receptors**, which facilitate viral entry. The following anatomical changes have been observed:

- **Inflammatory Infiltration of Cardiac Tissue:** Myocarditis (inflammation of the heart muscle) due to immune-mediated response.
- **Fibrotic Changes in the Myocardium:** Persistent scarring can lead to heart failure.
- **Increased Atherosclerotic Plaque Instability:** Can trigger acute coronary syndromes (heart attacks).
- **Microvascular Damage Leading to Ischemia:** Reduced blood supply to the heart and other organs due to damaged small vessels.

2. Respiratory System

COVID-19 primarily affects the lungs, causing **acute respiratory distress syndrome (ARDS)** and long-term lung damage. Key anatomical changes include:

- **Pulmonary Fibrosis:** Scarring of lung tissue, leading to reduced lung capacity and chronic shortness of breath.
- **Alveolar Damage and Hyaline Membrane Formation:** Leads to impaired gas exchange and hypoxia.
- **Bronchial Hyperreactivity:** Increased sensitivity of the airways, causing prolonged coughing and breathlessness.

- **Pulmonary Microthrombosis:** Formation of small clots in the lungs, increasing the risk of pulmonary hypertension.

3. Nervous System

Neurological symptoms in post-COVID-19 patients have raised concerns about the virus's impact on the brain and nervous system. Key changes include:

- **Neuroinflammation:** Inflammatory response in the brain leading to cognitive dysfunction, "brain fog," and fatigue.
- **White Matter Lesions and Microvascular Damage:** May contribute to memory loss, confusion, and an increased risk of neurodegenerative diseases.
- **Loss of Olfactory Bulb Neurons:** Explains persistent anosmia (loss of smell) in some patients.
- **Increased Risk of Stroke:** Due to hypercoagulability and endothelial dysfunction.
- **Autonomic Nervous System Dysregulation:** Leading to conditions like **Postural Orthostatic Tachycardia Syndrome (POTS),** which causes dizziness and rapid heart rate upon standing.

4. Renal (Kidney) System

COVID-19-associated kidney damage is a major concern, especially in critically ill patients. The virus affects the kidneys through **direct viral invasion and systemic inflammation.**

- **Acute Kidney Injury (AKI):** Occurs in severe COVID-19 cases due to hypoxia and systemic inflammation.
- **Glomerular and Tubular Damage:** Leads to proteinuria (protein in urine) and long-term kidney dysfunction.
- **Fibrosis and Chronic Kidney Disease (CKD):** Persistent damage increases the risk of end-stage renal disease.

5. Gastrointestinal System

The **gastrointestinal (GI) tract** is another key target due to the presence of ACE2 receptors. Post-COVID-19, patients have reported persistent digestive symptoms.

- **Intestinal Inflammation:** Chronic inflammation can lead to irritable bowel syndrome (IBS)-like symptoms.
- **Microbiome Dysbiosis:** An imbalance in gut bacteria may contribute to long-term digestive issues and immune dysfunction.

- **Liver Damage:** Elevated liver enzymes and hepatic inflammation (hepatitis) have been observed, especially in patients who received multiple medications during hospitalization.
- **Pancreatic Dysfunction:** Some studies suggest an increased risk of diabetes due to viral damage to pancreatic beta cells.

6. Musculoskeletal System

Post-COVID-19 symptoms include muscle pain, joint stiffness, and chronic fatigue, indicating musculoskeletal involvement.

- **Myopathy (Muscle Damage):** Viral invasion and inflammation can lead to muscle weakness.
- **Osteopenia and Osteoporosis:** Increased bone loss due to prolonged inactivity and inflammation.
- **Arthralgia and Joint Inflammation:** Many patients report persistent joint pain similar to autoimmune disorders.

7. Endocrine System

The hormonal system can also be affected by COVID-19, leading to metabolic disturbances.

- **New-Onset Diabetes Mellitus:** COVID-19 is linked to insulin resistance and pancreatic beta-cell damage.
- **Thyroid Dysfunction:** Cases of subacute thyroiditis (inflammation of the thyroid) and abnormal thyroid hormone levels have been reported.
- **Adrenal Insufficiency:** Possible long-term effects on the adrenal glands leading to fatigue and hypotension.

8. Immune System and Hematological Changes

COVID-19 disrupts immune homeostasis, leading to both **hyperactivation and suppression of immune function.**

- **Persistent Inflammatory State:** Chronic low-grade inflammation can contribute to autoimmunity and long COVID symptoms.
- **Lymphopenia (Low Lymphocyte Count):** Observed in many severe cases, making individuals vulnerable to infections.
- **Hypercoagulability:** Increased tendency for blood clot formation, leading to deep vein thrombosis (DVT), pulmonary embolism, and stroke.
- **Cytokine Storm Syndrome:** Excessive immune activation can lead to multi-organ damage.

WHY CARDIAC DISEASES INCREASED AFTER COVID-19

COVID-19 has significantly contributed to a rise in **cardiovascular diseases** among recovered patients. Several mechanisms explain this increase, including **persistent inflammation, vascular damage, and autonomic dysfunction**. The following factors contribute to the post-COVID-19 surge in cardiac conditions:

1. Persistent Systemic Inflammation

- After recovering from COVID-19, many individuals experience **chronic low-grade inflammation** in the body.
- Elevated levels of inflammatory markers like **C-reactive protein (CRP) and interleukin-6 (IL-6)** indicate ongoing immune activation, which can damage the heart and blood vessels over time.
- This **prolonged inflammatory state** contributes to conditions such as **myocarditis, pericarditis, and heart failure**.

2. Endothelial Dysfunction Leading to Clot Formation

- SARS-CoV-2 attacks the **endothelial cells** lining the blood vessels, leading to **vascular inflammation and increased clot formation**.
- This endothelial dysfunction increases the risk of **deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (heart attack), and stroke**.
- Even months after recovery, some patients experience **hypercoagulability (excessive clotting tendency)**, which can contribute to life-threatening cardiovascular events.

3. Direct Viral Injury to Cardiac Cells

- The **ACE2 receptors**, which SARS-CoV-2 uses to enter cells, are highly expressed in **heart tissues**.
- Direct invasion of the virus into **cardiomyocytes (heart muscle cells)** can lead to **myocardial inflammation, scarring, and fibrosis**, increasing the risk of **heart failure and arrhythmias**.
- **Autopsy reports and cardiac MRI studies** have revealed lingering heart muscle damage in recovered COVID-19 patients, even those with mild initial symptoms.

4. Increased Stress Response and Dysautonomia

- COVID-19 disrupts the **autonomic nervous system**, leading to **dysautonomia**—a condition affecting heart rate, blood pressure, and circulation.

- **Postural Orthostatic Tachycardia Syndrome (POTS)**, characterized by an abnormal heart rate increase upon standing, is now frequently observed in post-COVID-19 patients.
- **Persistent stress and anxiety** related to long COVID further exacerbate cardiovascular strain, increasing the risk of **hypertension and arrhythmias**.

5. Exacerbation of Pre-Existing Cardiovascular Conditions

- Patients with **hypertension, diabetes, or coronary artery disease (CAD)** are at higher risk of severe COVID-19 complications.
- The inflammatory and thrombotic effects of the virus can **accelerate the progression of pre-existing heart conditions**.
- COVID-19 also disrupts lipid metabolism, increasing **cholesterol levels** and the risk of **atherosclerosis**.

LIST OF CARDIAC DISEASES RAPIDLY NOTICED POST-COVID-19

Several cardiovascular conditions have been observed at an increased rate in post-COVID-19 patients:

1. Myocarditis

- **Inflammation of the heart muscle** due to direct viral invasion or an immune response.
- Can lead to **chest pain, fatigue, heart failure, and arrhythmias**.

2. Pericarditis

- **Inflammation of the pericardium (heart's outer lining)**, causing **chest pain and breathing difficulties**.
- Often associated with **fluid accumulation around the heart (pericardial effusion)**.



3. Arrhythmias

- **Atrial Fibrillation (AFib):** An irregular, often rapid heartbeat that increases stroke risk.
- **Ventricular Tachycardia (VT):** A dangerous fast heart rhythm that may require emergency intervention.
- **Bradycardia:** Abnormally slow heart rate due to autonomic dysfunction.

4. Heart Failure

- COVID-19-related **myocardial damage** can weaken the heart, leading to **heart failure** with symptoms like shortness of breath and fluid retention.
- Even in young, previously healthy individuals, **cardiac MRI studies have detected post-COVID structural heart damage**.

5. Myocardial Infarction (Heart Attack)

- Increased clotting tendency and **vascular inflammation** contribute to an **increased incidence of heart attacks** post-COVID.
- COVID-19 accelerates **plaque rupture in coronary arteries**, leading to **acute coronary syndromes**.

6. Pulmonary Embolism (PE)

- A life-threatening condition where **a blood clot travels to the lungs**, blocking circulation.
- COVID-19 significantly **increases the risk of PE** due to systemic hypercoagulability.

7. Stroke

- **Both ischemic and hemorrhagic strokes** have been observed at higher rates in COVID-19 survivors.
- **Younger individuals** without traditional stroke risk factors have also been affected.

8. Postural Orthostatic Tachycardia Syndrome (POTS)

- A condition were standing up causes an **abnormally high heart rate**, leading to dizziness, fatigue, and fainting.
- Post-COVID-19 autonomic dysfunction contributes to this **debilitating condition**, especially in younger adults.

MANAGEMENT OF POST-COVID-19 CARDIAC COMPLICATIONS

Due to the increasing burden of post-COVID cardiovascular diseases, a **multidisciplinary approach** is essential for long-term management.

1. Medications

- **Anticoagulants (Heparin, Apixaban):** To prevent blood clot formation.
- **Beta-Blockers (Metoprolol, Bisoprolol):** For arrhythmia and blood pressure control.
- **ACE Inhibitors (Ramipril, Enalapril):** To improve heart function in post-COVID heart failure.
- **Anti-Inflammatory Agents (Colchicine, Corticosteroids):** For myocarditis and pericarditis.

2. Lifestyle Modifications

- **Regular Exercise:** Low-impact activities like walking and yoga to improve cardiovascular endurance.
- **Heart-Healthy Diet:** Rich in **omega-3 fatty acids, antioxidants, and fiber** to reduce inflammation.
- **Stress Management:** Meditation, breathing exercises, and psychological support for post-COVID stress and anxiety.

3. Monitoring and Follow-Up

- **ECG & Holter Monitoring:** To detect post-COVID arrhythmias.
- **Echocardiography & Cardiac MRI:** To assess heart function and detect myocarditis or fibrosis.
- **D-Dimer & Troponin Levels:** To monitor clotting risk and myocardial injury.

4. Rehabilitation Programs

- **Cardiac Rehabilitation:** Supervised exercise therapy to restore heart function.
- **Pulmonary Rehabilitation:** For patients with combined lung and heart dysfunction.
- **Autonomic Nervous System Therapy:** To manage **POTS and dysautonomia** symptoms.

OBSERVATIONS

- **Increased incidence of cardiovascular complications** in recovered COVID-19 patients, regardless of initial disease severity.
- **Higher prevalence of heart-related issues** in individuals with **pre-existing conditions** (hypertension, diabetes, obesity).
- **Persistent post-COVID symptoms** such as **chest pain, palpitations, fatigue, and breathlessness** affecting quality of life.

- **Unexpected cardiac complications in younger patients** without prior heart disease history.

DISCUSSION

The impact of **COVID-19 on the cardiovascular system** is profound, affecting both previously healthy individuals and those with pre-existing conditions. The virus triggers a cascade of pathological changes, including **systemic inflammation, endothelial dysfunction, hypercoagulability, and direct myocardial injury**, all of which contribute to increased cardiovascular risk.

1. Mechanisms Behind Increased Cardiac Risk

COVID-19 affects the cardiovascular system through several mechanisms:

- **Persistent inflammation:** Even after viral clearance, elevated inflammatory markers like **C-reactive protein (CRP), interleukin-6 (IL-6), and ferritin** continue to influence vascular health.
- **Endothelial dysfunction and microvascular damage:** The virus directly infects endothelial cells, leading to vascular inflammation, clot formation, and increased risks of **heart attacks and strokes**.
- **Dysautonomia and stress response:** Post-COVID autonomic dysfunction leads to conditions like **Postural Orthostatic Tachycardia Syndrome (POTS)** and abnormal heart rate regulation.
- **Myocardial fibrosis and structural changes:** Many recovered COVID-19 patients exhibit long-term **fibrotic changes in the heart**, which can progress to **heart failure and arrhythmias**.

2. Need for Long-Term Follow-Up Studies

- While short-term studies have documented **myocarditis, arrhythmias, and thrombotic events**, the long-term cardiovascular impact remains unclear.
- Studies using **cardiac MRI scans** have shown **persistent myocardial inflammation and fibrosis** in post-COVID patients, even those who had mild or asymptomatic infections.
- Large-scale, multi-year follow-up studies are necessary to determine whether COVID-19 survivors have an increased lifetime risk of cardiovascular diseases such as **hypertension, coronary artery disease (CAD), or cardiomyopathy**.

3. Role of Vaccines in Preventing Severe Disease

- **COVID-19 vaccines** have been crucial in reducing the severity of illness and the risk of cardiovascular complications.
- While **mild, transient myocarditis cases** have been reported with mRNA vaccines, studies indicate that the **cardiac risk from COVID-19 itself is much higher** than the vaccine-associated risk.
- Public health efforts should focus on **increasing vaccine coverage, especially in high-risk populations**, to mitigate severe cardiac outcomes.

4. Public Health Strategies for Cardiac Disease Prevention

- **Early detection:** Regular **cardiac screening** for COVID-19 survivors, especially those with persistent symptoms like chest pain, palpitations, or breathlessness.
- **Risk stratification:** Identifying high-risk groups (e.g., individuals with **hypertension, diabetes, or obesity**) for close monitoring.
- **Post-COVID clinics and rehabilitation programs:** Establishing dedicated centers for **long-COVID cardiovascular care**, including **cardiac rehab, stress management, and dietary counseling**.

CONCLUSION

COVID-19 has significantly impacted cardiovascular health, leading to an increased burden of cardiac diseases such as myocarditis, arrhythmias, heart failure, and thromboembolic events. The pathophysiological changes induced by the virus contribute to long-term cardiovascular complications, emphasizing the need for ongoing monitoring and management strategies.

Understanding the full spectrum of post-COVID cardiac effects is crucial for reducing morbidity and mortality. Early intervention, appropriate medical management, lifestyle modifications, and rehabilitation programs are essential in mitigating long-term cardiovascular risks.

Further research is needed to develop targeted interventions and therapeutic strategies that address the specific challenges posed by post-COVID cardiovascular complications. Public health policies should prioritize prevention, early detection, and long-term cardiovascular care to improve outcomes for COVID-19 survivors.

REFERENCES

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*., 2020; 395(10229): 1054-62. Available from: https://doi.org/10.1016/S0140-6736(20)30566-3
2. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*., 2020; 26(7): 1017-32. Available from: https://doi.org/10.1038/s41591-020-0968-3
3. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med*., 2022; 28(3): 583-90. Available from: https://doi.org/10.1038/s41591-022-01689-3
4. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19. *JAMA Cardiol*, 2020; 5(11): 1265-73. Available from: https://doi.org/10.1001/jamacardio.2020.3557
5. Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. *Prog Cardiovasc Dis*., 2020; 63(5): 682-9. Available from: https://doi.org/10.1016/j.pcad.2020.05.013
6. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. *Am J Emerg Med*., 2020; 38(7): 1504-7. Available from: https://doi.org/10.1016/j.ajem.2020.04.048
7. Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J*., 2020; 41(32): 3038-44. Available from: https://doi.org/10.1093/eurheartj/ehaa623
8. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E, et al. Organ-specific manifestations of COVID-19 infection. *Clin Exp Med*., 2020; 20(4): 493-506. Available from: https://doi.org/10.1007/s10238-020-00648-x
9. Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? *Diabetes Care*, 2020; 43(7): 1408-15. Available from: https://doi.org/10.2337/dc20-0723
10. Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. *Circulation*, 2020; 142(1): 68-78. Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047549